A detailed history of Robeco Institutional Asset Management B.V. transactions in Bio N Tech Se stock. As of the latest transaction made, Robeco Institutional Asset Management B.V. holds 115,052 shares of BNTX stock, worth $13 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
115,052
Previous 138,634 17.01%
Holding current value
$13 Million
Previous $11.1 Million 22.66%
% of portfolio
0.03%
Previous 0.02%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$78.36 - $124.66 $1.85 Million - $2.94 Million
-23,582 Reduced 17.01%
115,052 $13.7 Million
Q2 2024

Jul 22, 2024

SELL
$80.36 - $102.87 $182,819 - $234,029
-2,275 Reduced 1.61%
138,634 $11.1 Million
Q1 2024

Apr 24, 2024

BUY
$88.96 - $112.35 $773,329 - $976,658
8,693 Added 6.57%
140,909 $13 Million
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $1.95 Million - $2.42 Million
21,426 Added 19.34%
132,216 $14 Million
Q4 2023

Feb 08, 2024

SELL
$90.91 - $112.75 $2.33 Million - $2.89 Million
-25,594 Reduced 18.77%
110,790 $132 Million
Q3 2023

Oct 23, 2023

BUY
$98.5 - $125.08 $1.59 Million - $2.02 Million
16,179 Added 13.46%
136,384 $14.8 Million
Q2 2023

Jul 24, 2023

BUY
$102.58 - $129.66 $4.66 Million - $5.9 Million
45,472 Added 60.85%
120,205 $13 Million
Q1 2023

May 03, 2023

BUY
$122.57 - $153.67 $5.87 Million - $7.36 Million
47,924 Added 178.76%
74,733 $9.31 Million
Q4 2022

Feb 06, 2023

BUY
$118.43 - $186.05 $3.17 Million - $4.99 Million
26,809 New
26,809 $4.03 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Robeco Institutional Asset Management B.V. Portfolio

Follow Robeco Institutional Asset Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.